Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
PeptidesDBan atlas
← CataloguePlate XXVII of XXX
XXVIIPlate XXVIIReviewed 2026-04-25

Tesofensine

Triple monoamine reuptake inhibitor (small molecule)

also known as NS2330

Originally developed for Alzheimer's and Parkinson's, tesofensine is a small-molecule (not technically a peptide) triple reuptake inhibitor of serotonin, norepinephrine, and dopamine. Phase 2b in obesity (Astrup Lancet 2008) demonstrated 9.2 kg weight loss at 0.5 mg/day over 24 weeks — among the largest non-GLP-1 weight-loss effects. Phase 3 trial in Mexico (Medix) ongoing. Listed for class completeness; not a peptide.

§ I

At a glance

Daily dose
0.25–0.5 mg
[astrup-2008-tesofensine]
Weight ↓ (24 wk)
9.2 kg
[astrup-2008-tesofensine]
Evidence level
Phase 3
[astrup-2008-tesofensine]
Route

Oral · Once daily morning

§ II

Mechanism

Primary target — Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT) [astrup-2008-tesofensine].

Pathway — Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesis [astrup-2008-tesofensine].

Downstream effect — Strong appetite suppression, mild thermogenic effect, weight loss [astrup-2008-tesofensine].

Origin — Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesity [astrup-2008-tesofensine].

§ III

Dosage

Protocols described in the cited literature; not medical advice.

ParameterValue
Standard dose0.25–0.5 mg / day [astrup-2008-tesofensine]
FrequencyOnce daily, morning
Lower / starter dose0.125 mg / day
Evidence basisPhase 2b + ongoing Phase 3 [astrup-2008-tesofensine]
Duration24 weeks per studied cycle
FormOral capsule
TimingMorning to avoid sleep disruption
Half-life~9 days (very long)
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Tesofensine's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
1.000mL
≈ 100.0 units on a U-100 insulin syringe
Concentration
250
mcg per mL
Doses per vial
2
at this dose
§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Heart rate / BPmoderate
Dose-dependent ↑ HR + BP [astrup-2008-tesofensine]
Insomniamoderate
Dose-related; mitigate with morning timing
Dry mouthmild
Common
Nauseamild
Common
Mood changesmoderate
Anxiety / agitation possible
Cardiovascular eventssevere
Phase 3 trial monitoring; not yet FDA-cleared
Pregnancy / OBsevere
Contraindicated
Absolute contraindications
  • — Pregnancy / breastfeeding
  • — Severe cardiovascular disease
  • — Concurrent MAOI use
Relative contraindications
  • — Hypertension
  • — Anxiety disorder
  • — Insomnia
§ VI

Administration

  1. 01
    Form

    Oral capsule (investigational; not commercial).

  2. 02
    Administration

    Swallow whole with water, morning only.

  3. 03
    Timing

    Morning to mitigate insomnia. Do not dose evening.

  4. 04
    Storage

    Room temp ≤25 °C, dry place.

  5. 05
    Caveat

    Monitor BP + HR + mood. Avoid stimulants + MAOIs.

Appendix

Sources

25%

of 40 rendered claims carry a resolvable citation.

  1. [astrup-2008-tesofensine]
    Astrup 2008 — Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients
    Lancet, 2008
    PubMed →
Plate composed 2026-04-25 · maturity draft · schema v1 · Contributors: peptidesdb-core · 30 fields uncited — open contributions
Edit on GitHub →Read another →